US Stock Insider Trading | Viridian Disclosed Four Insider Transactions on March 9

K-LinePoet · 2026-03-18T09:51:06+00:00

Viridian (VRDN) disclosed executive insider trading activity on March 9, 2026. Executive Mahoney sold 7,408 shares on March 3 for a total value of $223,600. The company focuses on research and development of biopharmaceuticals targeting rare diseases, with three candidate products currently in development.

K-LinePoet

2026-03-18 09:51:06

Abstract generation in progress

On March 9, 2026, Viridian (VRDN) disclosed four insider transactions. Executive Mahoney Stephen F. sold 7,408 shares on March 3, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 9, 2026	Executive	Mahoney Stephen F.	March 3, 2026	Sell	7,408	30.19	$223,600
March 9, 2026	Executive	Harmon Seth	March 3, 2026	Sell	2,031	30.19	$61,300
March 9, 2026	Executive	Beetham Thomas W.	March 3, 2026	Sell	3,048	30.19	$92,000
March 9, 2026	Executive	Tousignant Jennifer	March 3, 2026	Sell	1,675	30.19	$50,600
January 2, 2025	Executive	Tousignant Jennifer	December 31, 2025	Sell	2,272	31.16	$70,800
October 27, 2025	Shareholder with >10%	Fairmount Funds Management LLC	October 23, 2025	Buy	454,500	22.00	$10,000,000
June 11, 2025	Shareholder with >10%	Fairmount Funds Management LLC	June 9, 2025	Buy	1,600	7.80	$12,500
June 11, 2025	Shareholder with >10%	Fairmount Funds Management LLC	June 10, 2025	Buy	12,500	12.31	$153,900
September 30, 2024	Executive	Beetham Thomas W.	September 27, 2024	Buy	5,000	23.41	$117,100
September 30, 2024	Director	Mahoney Stephen F.	September 27, 2024	Buy	21,400	23.33	$499,300

[Company Profile]

Viridian Therapeutics, Inc. was incorporated in Delaware on June 17, 2014. The company is a biopharmaceutical firm focused on researching and developing potential best-in-class drugs for severe and rare diseases. The company targets less competitive disease areas where existing therapies often leave room for improved efficacy, safety, or convenience. The company believes that first-generation drugs rarely represent the best solutions, especially in rare diseases, and has the potential to develop differentiated, best-in-class drugs to improve patient outcomes, reduce side effects, enhance quality of life, expand market access, and strengthen market competition. The company is developing three candidate products: VRDN-001, VRDN-002, and VRDN-003, which are in development for intravenous or subcutaneous administration to treat patients with thyroid eye disease (TED). Its most advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R for the treatment of TED.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.